Aeolus Pharmaceuticals, Inc., a biotechnology company developing a novel platform of compounds to treat radiation and chemical exposure, as well as oncology indications, today announced that NIH CounterACT has awarded a $735,951 contract to Manisha Patel, Ph.D., at the University of Colorado Anschutz Medical Campus. The funding is to support the development of AEOL 10150, Aeolus’ broad-spectrum catalytic antioxidant, as a medical countermeasure (MCM) against nerve agents.
The grant was awarded with primary objectives in mind, including the evaluation of the neuroprotective efficacy of AEOL 10150 against pilocarpine (an organic compound of plant origin)-induced neurotoxicity in rat models; exposure to nerve agents, metabolic poisons, or high levels of sulfur mustard can cause seizures and unconsciousness.
Aeolus said the two-year award builds on research conducted by Dr. Patel in rodent models of neurotoxicity and neurodegeneration. Dr. Patel’s studies have demonstrated that oxidative stress plays a central role in seizure-induced brain injury. Oxidative stress plays a key role in seizure-induced brain injury. Since nerve agents provoke seizures, it is vital to determine AEOL 10150’s neuroprotective abilities against such agents.
“We are pleased to see the expansion of the research and development of AEOL 10150 as a broad spectrum medical countermeasure, and are grateful for the support that NIH CounterACT provides for the development of this promising compound. With this project, the U.S. Government is now funding research and testing of AEOL 10150 in five MCM indications,” John L. McManus, president and CEO of Aeolus stated in the press release.
Aeolus noted that previous studies have also shown AEOL 10150 as an effective countermeasure to protect the lungs from damage due to inhalation of chlorine gas and sulfur mustard gas. The compound is currently being developed for a wide variety of applicable medical countermeasures with support from the U.S. Government.
Product Funding Review:
NIH CounterACT is funding research and development of the compound as a countermeasure against exposure to nerve agents, chlorine gas and sulfur mustard gas. NIH-NIAID is conducting animal efficacy studies of the compound as a countermeasure for the Gastro-Intestinal (GI) effects of Acute Radiation Syndrome (ARS); and the Biomedical Advanced Research and Development Authority (BARDA) has awarded the Aeolus a contract valued up to $118 million to develop AEOL 10150 as a countermeasure against Lung ARS/Delayed Effects of Radiation Exposure (DEARE).
For more information visit www.aeoluspharma.com
About QualityStocks:
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment